These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28650383)

  • 1. Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation.
    Lee JS; Cole SR; Richardson DB; Dittmer DP; Miller WC; Moore RD; Kitahata M; Mathews C; Mayer K; Geng E; Achenbach CJ; Eron JJ;
    AIDS; 2017 Sep; 31(14):1989-1997. PubMed ID: 28650383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer risk in HIV patients with incomplete viral suppression after initiation of antiretroviral therapy.
    Lee JS; Cole SR; Achenbach CJ; Dittmer DP; Richardson DB; Miller WC; Mathews C; Althoff KN; Moore RD; Eron JJ;
    PLoS One; 2018; 13(6):e0197665. PubMed ID: 29870537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy.
    Scott Sutton S; Magagnoli J; Hardin JW
    Pharmacotherapy; 2016 Apr; 36(4):385-401. PubMed ID: 26923931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control.
    Assoumou L; Weiss L; Piketty C; Burgard M; Melard A; Girard PM; Rouzioux C; Costagliola D;
    AIDS; 2015 Sep; 29(15):2003-7. PubMed ID: 26355572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.
    Teira R; Vidal F; Muñoz-Sánchez P; Geijo P; Viciana P; Ribera E; Domingo P; Castaño M; Martínez E; Roca B; Puig T; Estrada V; Deig E; Galindo MJ; de la Fuente B; Lozano F; Montero M; Muñoz-Sanz A; Sanchez T; Terrón A; Romero-Palacios A; Lacalle JR; Garrido M; Suárez-Lozano I;
    HIV Med; 2017 Mar; 18(3):196-203. PubMed ID: 27476742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytomegalovirus viremia in Thai HIV-infected patients on antiretroviral therapy: prevalence and associated mortality.
    Durier N; Ananworanich J; Apornpong T; Ubolyam S; Kerr SJ; Mahanontharit A; Ferradini L; Ruxrungtham K; Avihingsanon A
    Clin Infect Dis; 2013 Jul; 57(1):147-55. PubMed ID: 23511301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of CD4 Cell Counts and Viral Load Testing on Mortality Rates in Patients With HIV Infection Receiving Antiretroviral Treatment: An Observational Cohort Study in Rural Southwest China.
    Shen Z; Zhu Q; Tang Z; Pan SW; Zhang H; Jiang H; Chen Y; Lan G; Xing H; Liao L; Feng Y; Ruan Y; Shao Y
    Clin Infect Dis; 2016 Jul; 63(1):108-14. PubMed ID: 27001800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized Clinical Trial.
    Labhardt ND; Ringera I; Lejone TI; Klimkait T; Muhairwe J; Amstutz A; Glass TR
    JAMA; 2018 Mar; 319(11):1103-1112. PubMed ID: 29509839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
    Brumme ZL; Henrick BM; Brumme CJ; Hogg RS; Montaner JS; Harrigan PR
    Antivir Ther; 2005; 10(7):849-53. PubMed ID: 16312181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viremia copy-years and mortality among combination antiretroviral therapy-initiating HIV-positive individuals: how much viral load history is enough?
    Wang R; Haberlen SA; Palella FJ; Mugavero MJ; Margolick JB; Macatangay BJC; Martínez-Maza O; Jacobson LP; Abraham AG
    AIDS; 2018 Nov; 32(17):2547-2556. PubMed ID: 30379686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy.
    Raboud J; Blitz S; Walmsley S; Thompson C; Rourke SB; Loutfy MR;
    HIV Clin Trials; 2010; 11(6):340-50. PubMed ID: 21239362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.
    Laprise C; de Pokomandy A; Baril JG; Dufresne S; Trottier H
    Clin Infect Dis; 2013 Nov; 57(10):1489-96. PubMed ID: 23946221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.
    Suaysod R; Ngo-Giang-Huong N; Salvadori N; Cressey TR; Kanjanavanit S; Techakunakorn P; Krikajornkitti S; Srirojana S; Laomanit L; Chalermpantmetagul S; Lallemant M; Le Cœur S; McIntosh K; Traisathit P; Jourdain G
    Clin Infect Dis; 2015 Jul; 61(1):95-101. PubMed ID: 25838288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.
    Mocroft A; Phillips AN; Gatell J; Ledergerber B; Fisher M; Clumeck N; Losso M; Lazzarin A; Fatkenheuer G; Lundgren JD;
    Lancet; 2007 Aug; 370(9585):407-13. PubMed ID: 17659333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality.
    Glass TR; Sterne JA; Schneider MP; De Geest S; Nicca D; Furrer H; Günthard HF; Bernasconi E; Calmy A; Rickenbach M; Battegay M; Bucher HC;
    AIDS; 2015 Oct; 29(16):2195-200. PubMed ID: 26544582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US.
    Antiretroviral Therapy Cohort Collaboration (ART-CC)
    Antivir Ther; 2015; 20(1):21-8. PubMed ID: 24675571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment.
    Elvstam O; Medstrand P; Yilmaz A; Isberg PE; Gisslén M; Björkman P
    PLoS One; 2017; 12(7):e0180761. PubMed ID: 28683128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
    Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT;
    J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.